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Overview of the market
Reduction in risk of cardiovascular disease (CVD) morbidity and mortality via reduction of lowdensity lipoprotein cholesterol (LDL-C) has been shown to be effective in both primary [1] and secondary [2] prevention of CV events [3] . This approach became possible with the introduction of statins, drugs that target the mevalonate pathway downstream of adenosine triphosphate-citrate lyase (ACL) by inhibition of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA reductase), the rate-limiting step in cholesterol biosynthesis. This has been a remarkably successful and consistent approach to cardiovascular disease risk reduction. The Cholesterol-Treatment
Trialists' collaborators performed a meta-analysis of 14 randomized controlled trials (RCTs) and concluded that lowering plasma concentrations of LDL-C by 1 mmol/L (38.7 mg/dl) reduced the risk of major coronary events by 23% over 5 years. The greatest benefit was seen in those who had had a previous cardiovascular (CV) event, but a substantial reduction in CVD was also observed in a primary prevention population [4] .
Recent developments have enabled more substantial reductions in plasma LDL-C, an approach that would appear to result in a further reduction of CV risk. The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) investigated combination therapy with simvastatin and ezetimibe in secondary prevention. The combination led to lower LDL-C levels (53.7 vs 69.5 mg/dL) than simvastatin monotherapy, and importantly this translated to reduced risk of the primary endpoint, which was a composite of cardiac events (hazard ratio [HR] 0.936 [0.89 to 0.99]) [5] . However, surprisingly, despite these positive and significant results the US Food and Drug Administration (FDA) did not approve ezetimibe for use as an addition to statin therapy for reduction of CV events in patients with coronary heart disease (CHD) [6, 7] .
A new class of lipid lowering agents, the proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-i) have recently been approved for LDL-C lowering in multiple countries.
They show a substantial reduction in LDL-C levels. The ODYSSEY-LONG TERM trial, which recruited participants with heterozygous familial hypercholesterolemia (HeFH), CHD or a risk equivalent, demonstrated substantial reductions in LDL-C after treatment with alirocumab, a monoclonal antibody inhibitor of PCSK9 protein, when used with a statin [8, 9] . These LDL-C lowering results complement those of the OSLER study, which utilized evolocumab, another PCSK9 inhibitor [10] . Both studies showed significant reduction of CV events with PCSK9
inhibitors (however it is worth mentioning that these studies were neither designed nor powered to investigate CV outcomes) and confirmed the safety of LDL-C reduction, to levels even below 25 mg/dL [6, 7] . The results of the cardiovascular outcomes trials (CVOT) with these agents (FOURIER, ODYSSEY OUTCOMES) are expected in 2017 and 2018 [11, 12] .
However, the effectiveness of LDL-C lowering therapy in clinical practice has been limited by a number of factors, including poor adherence to statin therapy, statin discontinuation [13] and statin intolerance [14] and residual risk despite achieving therapeutic LDL-C targets [6, 15] . Statin monotherapy or combinations of currently available drugs are unlikely to achieve optimal concentrations of LDL-C in all patients, especially those who are at high CV risk [16] . Despite the fact that statins are very well tolerated, they do have well documented adverse effects, mainly muscle-related adverse events, and PCSK9 inhibitors require subcutaneous injection, which may not be acceptable or convenient for all patients. Lipid reduction by ezetimibe as monotherapy is limited [17] . Thus, despite the benefits conferred by these drugs, there is an urgent clinical need for new LDL-C lowering therapies, which can be demonstrated to significantly reduce elevated LDL-C levels and limit adverse effects, either as monotherapy or in combination with existing drugs. Bempedoic acid shows early promise in this regard.
Introduction to Bempedoic Acid
Bempedoic acid (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid, ETC-1002, developed by Esperion Therapeutics Inc., is a novel lipid regulating drug with a unique mechanism of action. It is a prodrug that is converted to bempedoic acid-CoA -a competitive inhibitor of the enzyme ACL. Conversion of bempedoic acid to the active form (ETC-1002 CoA) occurs preferentially in the liver [18] . ACL is the enzyme responsible for hepatic production of cytosolic acetyl-coenzyme A, the precursor of the mevalonate pathway of cholesterol biosynthesis. The predominant biochemical manifestation of bempedoic acid therapy is an increase in low density lipoprotein (LDL)-receptor activity and a subsequent reduction in plasma concentrations of LDL-C [18] .
The mechanism of action of bempedoic acid, as understood from preclinical studies and the results of clinical trials, was extensively discussed in a review published in 2014 [19] , and, more recently, presented at the Scientific Sessions of the American Heart Association in 2015. The definitive mechanism of action of bempedoic acid has just been published [20] . New clinical evidence and an improved understanding of the mechanism of action of bempedoic acid have provoked this update. We aim to give an overview of all aspects of this promising new agent, with a particular focus on the results of Phase 2 clinical trials and recent experimental studies.
Pharmacology and mechanism of action of bempedoic acid
The predominant biochemical manifestations of bempedoic acid administration are an increase in LDL receptor activity and consequent reduction in the plasma concentration of LDL-C [18] . In relation to its LDL-C lowering effect, bempedoic acid is a prodrug of ETC-1002-Coenzyme A (ETC-1002-CoA). ETC-1002-CoA acts as a competitive inhibitor of the enzyme adenosine triphosphate-citrate lyase and reduces the production of cytosolic acetyl-coenzyme A, the precursor of the mevalonate pathway of cholesterol biosynthesis [18] . ACL is a unique target for LDL-C and CV risk reduction because it produces precursors required for both fatty acid and cholesterol synthesis [21] (Figure 1 ). Genetic inhibition of ACL has been shown to up-regulate LDL receptor expression and activity in McArdle cells [18] . Polymorphisms of ACLY, the gene encoding ACL have been linked with varying growth traits in cattle [22] and altered plasma triglyceride responses to fish-oil supplementation in humans [23] .
The mechanism by which bempedoic acid is converted to the active form, ETC-1002-CoA, has been extensively investigated in preclinical experiments [24] . It has been demonstrated that bempedoic acid is converted into ETC-1002-CoA by hepatic acyl-CoA synthetase (ACS) [18] , a family of enzymes, which catalyse the CoA thioesterification of fatty acids and thereby regulate the distribution and trafficking of fatty acids into complex lipids [25] . In particular, very longchain acyl-CoA synthetase 1 (ACSVL1) has been identified as the specific isoform of ACS responsible for activation of bempedoic acid to ETC-1002-CoA [18] . ETC-1002-CoA formation correlates with ACSVL1 expression in human liver subcellular fractions, and genetic silencing of ACSVL1 with small interfering RNAs (siRNAs) has been shown to prevent formation of bempedoic acid-CoA in McArdle cells. ACSVL1 is highly expressed in human liver microsomes, only modestly expressed in kidney, and has not been detected in skeletal muscle cells [18] . Thus, the distribution of ACSVL1 (and therefore the sites of ETC-1002-CoA activity) would appear to be ideal to allow perturbation of hepatic cholesterol synthesis, with minimal effects in other tissues [18] . In particular, the absence of ASCVL1 (and therefore ETC-1002-CoA) in skeletal muscle may allow effective LDL-C-lowering with reduced risk of muscle-related adverse events. [33] . And likewise, hsCRP was reduced significantly in the treated vs placebo group (p=0.0022).
Bempedoic acid in patients with type 2 diabetes mellitus
62% of patients randomized to bempedoic acid achieved LDL-C goals, compared with none in the placebo group (p<0.0001). There was no statistically significant difference between the groups in terms of HDL-C, triglycerides, apoA-I, Lp(a) or free fatty acids.
Adverse events were reported by 79% of patients treated with placebo, and 70% treated with bempedoic acid. These led to discontinuation in 16% of patients in the placebo group and 14% in bempedoic acid group. A similar percentage of placebo and bempedoic acid treated patients (32 vs 27%) reported muscle adverse effects, and 16% of placebo treated patients withdrew due to muscle-related side-effects, whereas importantly there were no discontinuations because of muscle-related side effects in the bempedoic acid group [33] .
Bempedoic acid and ezetimibe combined therapy
Combination therapy with ezetimibe (which reduces cholesterol absorption by blocking
Niemann-Pick C1-like 1 proteins on intestinal epithelial cells) [6] and bempedoic acid (which reduces hepatic cholesterol biosynthesis leading to up-regulation of the LDLR), is a rational multitarget approach to lipid lowering. This tactic has been shown to lower LDL-C by up to 48%.
Ezetimibe is commonly used in statin intolerant patients [46] , however, its ability to lower LDL-C as a monotherapy is limited. Thus the combined use of ezetimibe and bempedoic acid in statin intolerant patients has potential value in terms of improved LDL-C goal attainment.
A study evaluating the combination of bempedoic acid (120 or 180 mg daily) with ezetimibe (10mg daily) was compared with monotherapy of each drug in a 12 week trial, which randomized 349 patients, and included patients with good adherence to statin therapy and statin intolerant patients (ETC-1002-008, NCT01941836). In this study statin intolerance was defined as the inability to tolerate at least two statins, including one statin at the lowest approved dose due to muscle-related symptoms such as pain, aches, weakness, or cramping that began or increased during statin therapy and resolved when statin therapy was discontinued. Monotherapy with bempedoic acid resulted in very similar effects on lipid profiles to those seen in the studies described above [31] [32] [33] . LDL-C was reduced by 27.5±1.3% (least-squares mean ± standard error)
by the 120mg dose. The 180 mg dose resulted in a reduction of 30.1±1.3%. Reductions were also seen in apoB, LDL particle number, total cholesterol and non-high-density lipoprotein cholesterol, (non-HDL-C).
In common with previous trials [31 -33] , use of bempedoic acid was associated with a reduction in hsCRP (by 30.1% with 120mg and by 40.2% with 180mg) [37] . Ezetimibe monotherapy was also associated with reductions of LDL-C, LDL particle number, total cholesterol and non-HDL cholesterol, but in all cases these reductions were smaller than the reductions achieved by bempedoic acid, and the differences between the ezetimibe group and the bempedoic acid groups were statistically significant. Ezetimibe was associated with an increase in HDL-C of 5.0±1.4%.
Combined therapy led to greater reductions in LDL-C -120 mg bempedoic acid + 10 mg ezetimibe 
Ongoing research
It has been previously observed that bempedoic acid reduced blood pressure ( Europe, and will receive a daily dose of 180 mg bempedoic acid or placebo. Importantly, this trial is recruiting patients with diagnosed ASCVD and/or HeFH, thus it will enable evaluation of bempedoic acid in patients at the very highest levels of risk [38] .
Another study -A randomized, double-blind, placebo-controlled study to assess the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant (ETC-1002-043) will soon be initiated [49] . This trial will include approximately 12,600 adult male and female patients ≥18
years of age with inability to tolerate two or more statins, one at a low dose, due to adverse safety effects that started or increased during statin therapy, and resolved or improved when statin therapy was discontinued. Low dose statin therapy (LDST) is defined as less than an average starting daily dose of rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg, lovastatin 20 mg, pravastatin 40 mg, fluvastatin 40 mg, or pitavastatin 2 mg. The investigators assumed that patients who tolerate very low dose statin therapy (less than LDST as outlined above) are considered to be intolerant to that low dose statin and may qualify for the study. Patients may continue taking very low dose statin therapy throughout the study provided that it is stable (used for at least four weeks prior to screening) and well tolerated. In this double blind study patients will be randomized 1:1 to either bempedoic acid (180 mg) or placebo once daily. The primary objective in this study is to evaluate whether long-term treatment with bempedoic acid reduces the risk of major adverse cardiovascular events (MACE) in patients with, or at high risk for CVD who are statin intolerant [49] .
Conclusion
The reduction of LDL-C (as well as non-HDL-C, apoB and total cholesterol) and hsCRP demonstrated as monotherapy and in combination with statins and ezetimibe by bempedoic acid in phase 2 clinical trials suggest that bempedoic acid has potential for CV risk reduction by modulation of both lipids and inflammation. Early results would suggest that this can potentially be achieved with a reduced risk of muscle-related adverse events, which might limit the utilization and effectiveness of statin therapy. Table 2 is a SWOT analysis relating to the potential use of bempedoic acid. A CVOT is planned to determine whether the potential of bempedoic acid is realized in the reduction in risk of CV events and death.
Expert Opinion
The effects of bempedoic acid on the lipid profile and other biochemical parameters such as hsCRP would suggest that it has the potential to reduce the risk of CVD in a variety of situations and in combination with other lipid-lowering agents. Outcomes data are now required in order to determine whether CV events are reduced by therapy with bempedoic acid. A planned cardiovascular outcome trial (CVOT) will determine the effects of bempedoic acid on the risk of CV events and mortality. Previously published trials with bempedoic acid were associated with low rates of muscle related adverse effects. Larger clinical studies with bempedoic acid will investigate these adverse effects and also assess the incidence of less common adverse events.
Ongoing and future trials may be able to answer questions that current data cannot. Large well- 6. Acknowledgements:
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